GENE ONLINE|News &
Opinion
Blog

2020-07-17| PartnerAsia-Pacific

ITALY AT BIO ASIA TAIWAN 2020 – ONLINE

by GeneOnline
Share To

ITALY will once more be part of this trade show, at BIO ASIA TAIWAN 2020 – ONLINE.

The Italian pavilion, organized by ITA – Italian Trade Agency – and Italian Ministry of Foreign Affairs and International Cooperation will feature a delegation of 7 leading Italian biotech companies that encompass new biopharma, 3D medical printing, biotech services and bioindustry park.

3DIFIC S.r.l., a medical 3d printing company. They focus on a deep interaction with surgeons to understand precisely their necessities. They support doctors, scientists, and students to provide doctors with any patient-specific device they want.

The BIOINDUSTRY PARK SILVANO FUMERO S.p.a. which is located in the Piedmont region. The cluster of Piedmont gathers about 100 companies, research centers, R&D organizations and academic institutions in the healthcare sector. It has acted as a system integrator for the development of Life Sciences since its creation in 1998. Connect with them to find out about those companies and the Bioindustry Park.

In recent years IBSA FARMACEUTICI S.r.l. Italia has increased, becoming a significant economic and scientific company in the Italian pharmaceutical sector. Research and Development activities use advanced technology to study innovative methods for administering drugs. Today IBSA Farmaceutici Italia guarantees a vast number of products, ranging from people’s wellbeing to care and prevention, and covers 12 main therapeutic areas: Cardiometabolic, Dermatology, Dermo-aesthetic, Endocrinology, Human Reproduction, Osteoarticular, Pain and Inflammation, Respiratory, Urology, Ophthalmics, Otorhinolaryngology and Consumer Health.

For biopharmaceutical and med-tech companies that want to adopt global business development strategy, PHARMA & BIOTECH ADVISORS S.r.l. from Italy provides clients to solve their problems in strategy, operations, organization and change. Especially in advising firms in-licensing and alliances, portfolio management and emerging therapeutic/technological areas.

On the cell biotechnology field, REMEMBRANE S.r.l., an ISO 9001:2015 certified European SME. Its technology includes envisaging the cell membrane network and its lipid composition as a cornerstone of cell physiology. Remembrane designs, develops, and manufactures customised GMP-grade membrane-targeting Lipid Mixtures commercialized under the brand name Refeed.

SYNAPTICOM S.r.l.‘s patented active ingredients are supported by preclinical and clinical research and combined with innovative formulas, which are now widely used in therapy. The research results generated a “Drug-non-Drug” product platform registered as cosmetics and supplements, adding higher scientific value, thereby opening up a whole new market. Their most advanced pharmaceutical technology enables them to improve the bioavailability and effectiveness of the preparation.

VERA SALUS RICERCA S.r.l.’s an innovative biopharma company whose core capability is to discover best-in-class drug candidates that originated from natural compounds. Research is led by Prof. Giovanni Pitari from T. Jefferson University of Philadelphia, in collaboration with the Italian National Council for Research (CNR).

It is exciting to find out more about them in company presentations or virtual exhibitions during BIO Asia-Taiwan. You may also connect with their CEOs and executives during the one-on-one partnering event from July 22 to 26.

* Those Italian companies will be on July 24 in the company presentation section according to the schedule below!

24th, July, 2020

19:30 – 19:40 Vera Salus Ricerca S.r.l.
19:40 – 19:50 3DIFIC S.r.l.
19:50 – 20:00 Bioindustry Park Silvano Fumero S.p.a.
20:00 – 20:10 IBSA Farmaceutici S.r.l.
20:10 – 20:20 Pharma & Biotech Advisors S.r.l.
20:20 – 20:30 Remembrane S.r.l.
20:30 – 20:40 Synapticom S.r.l.

 

Make sure to sign up and check out those companies at the company presentation!

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Investment Summit Highlights: Advancements in Therapeutics & Pharmaceuticals
2024-08-02
BIO Asia-Taiwan Kicks Off with the Latest Cell and Gene Therapy Developments
2024-07-24
R&D
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
LATEST
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
Pfizer Pulls Sickle Cell Treatment Over Deadly Complication Risks
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top